158 related articles for article (PubMed ID: 34697490)
1. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects.
Wang C; Zhang W; He Y; Gao Z; Liu L; Yu S; Hu Y; Wang S; Zhao C; Li H; Shi J; Zhou W; Li F; Yue H; Li Y; Wei W; Ma G; Ma D
Nat Nanotechnol; 2021 Dec; 16(12):1413-1423. PubMed ID: 34697490
[TBL] [Abstract][Full Text] [Related]
2. Targeted cancer cell delivery of arsenate as a reductively activated prodrug.
Cioloboc D; Kurtz DM
J Biol Inorg Chem; 2020 May; 25(3):441-449. PubMed ID: 32189144
[TBL] [Abstract][Full Text] [Related]
3. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
4. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
[TBL] [Abstract][Full Text] [Related]
5. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
6. High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors.
Falvo E; Damiani V; Conti G; Boschi F; Messana K; Giacomini P; Milella M; De Laurenzi V; Morea V; Sala G; Fracasso G; Ceci P
J Exp Clin Cancer Res; 2021 Feb; 40(1):63. PubMed ID: 33568214
[TBL] [Abstract][Full Text] [Related]
7. CD71-Specific Aptamer Conjugated with Monomethyl Auristatin E for the Treatment of Uveal Melanoma.
Zhang H; Jin C; Zhang L; Peng B; Zhang Y; Liu Y; Li L; Ye M; Xiong W; Tan W
ACS Appl Mater Interfaces; 2022 Jan; 14(1):32-40. PubMed ID: 34928139
[TBL] [Abstract][Full Text] [Related]
8. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.
Etchin J; Sanda T; Mansour MR; Kentsis A; Montero J; Le BT; Christie AL; McCauley D; Rodig SJ; Kauffman M; Shacham S; Stone R; Letai A; Kung AL; Thomas Look A
Br J Haematol; 2013 Apr; 161(1):117-27. PubMed ID: 23373539
[TBL] [Abstract][Full Text] [Related]
9. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
10. Self-assembling ferritin-dendrimer nanoparticles for targeted delivery of nucleic acids to myeloid leukemia cells.
Palombarini F; Masciarelli S; Incocciati A; Liccardo F; Di Fabio E; Iazzetti A; Fabrizi G; Fazi F; Macone A; Bonamore A; Boffi A
J Nanobiotechnology; 2021 Jun; 19(1):172. PubMed ID: 34107976
[TBL] [Abstract][Full Text] [Related]
11. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
12. [Arsenic: The gold standard for acute promyelocytic leukaemia with FLT3-ITD mutation].
Esnault C; Rahmé R; de Thé H
Med Sci (Paris); 2021 May; 37(5):544-546. PubMed ID: 34003103
[No Abstract] [Full Text] [Related]
13. Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth.
Vine KL; Indira Chandran V; Locke JM; Matesic L; Lee J; Skropeta D; Bremner JB; Ranson M
Curr Cancer Drug Targets; 2012 Jan; 12(1):64-73. PubMed ID: 22111834
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
15. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles.
Qian C; Wang Y; Chen Y; Zeng L; Zhang Q; Shuai X; Huang K
Biomaterials; 2013 Aug; 34(26):6175-84. PubMed ID: 23721794
[TBL] [Abstract][Full Text] [Related]
16. Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.
Aznab M; Rezaei M
Hematol Oncol; 2017 Mar; 35(1):113-117. PubMed ID: 26310595
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide in the management of acute promyelocytic leukaemia.
Mathews V; Chandy M; Srivastava A
Natl Med J India; 2001; 14(4):215-22. PubMed ID: 11547528
[TBL] [Abstract][Full Text] [Related]
19. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
20. Ferritin nanocages for early theranostics of tumors via inflammation-enhanced active targeting.
Jiang B; Jia X; Ji T; Zhou M; He J; Wang K; Tian J; Yan X; Fan K
Sci China Life Sci; 2022 Feb; 65(2):328-340. PubMed ID: 34482518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
